Press Releases

CRANBURY, N.J., Feb. 8, 2012 /PRNewswire/ — Palatin Technologies, Inc. (NYSE Amex: PTN) will announce its second quarter, fiscal year 2012 financial results on Wednesday, February 15, 2012 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on February […]

CRANBURY, N.J., Jan. 17, 2012 /PRNewswire/ — Palatin Technologies, Inc. (NYSE Amex: PTN) announced today it has received net proceeds of approximately $1.1 million of non-dilutive funding through the New Jersey Economic Development Authority’s tax credit transfer program.  Palatin Technologies sold both New Jersey net operating losses and research and development tax credits to unrelated corporations.

CRANBURY, N.J., Jan. 16, 2012 /PRNewswire/ — Palatin Technologies, Inc. (NYSE Amex: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced that Dr. Carl Spana, President and Chief Executive Officer will present at BOCEMb, Noble Financial Capital Markets’ Eighth Annual Equity

CRANBURY, N.J., Nov. 30, 2011 /PRNewswire/ — Palatin Technologies, Inc. (NYSE Amex: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced that Dr. Carl Spana, President and Chief Executive Officer, will be presenting at Windhover’s Therapeutic Area Partnerships conference on

CRANBURY, N.J., Nov. 10, 2011 /PRNewswire/ — Palatin Technologies, Inc. (NYSE Amex: PTN) will announce its first quarter, fiscal year 2012 financial results on Tuesday, November 15, 2011 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on November

CRANBURY, N.J., Sept. 22, 2011 /PRNewswire/ — Palatin Technologies, Inc. (NYSE Amex: PTN), a biopharmaceutical company developing bremelanotide for sexual dysfunction indications and PL-3994 for acute asthma and other indications, today announced results for its fourth quarter and fiscal year ended June 30, 2011.   Recent Highlights Palatin initiated enrollment in its Phase 2B trial

CRANBURY, N.J., Sept. 19, 2011 /PRNewswire/ — Palatin Technologies, Inc. (NYSE Amex: PTN) will announce its fourth quarter, fiscal year 2011 financial results on Thursday, September 22, 2011 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on September

CRANBURY, N.J., Sept. 9, 2011 /PRNewswire/ — Palatin Technologies, Inc. (NYSE Amex: PTN) announced that it will be presenting at the Rodman & Renshaw Annual Global Investment Conference on Tuesday, September 13, 2011, at 12:05 p.m. Eastern Time.  The conference will be held at The Waldorf Astoria in New York, NY. Carl Spana, Ph.D., President

CRANBURY, N.J., Aug. 4, 2011 /PRNewswire/ — Palatin Technologies, Inc. (NYSE Amex: PTN) confirmed today the commencement of a Phase 1 clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist, under development as a single-agent therapy for the treatment of obesity. AZD2820 is a clinical candidate selected by AstraZeneca from its collaborative research

CRANBURY, N.J., June 23, 2011 /PRNewswire/ — Palatin Technologies, Inc. (NYSE Amex: PTN) announced today that Alan W. Dunton, M.D., formally joined Palatin’s Board of Directors on June 22, 2011 as an independent director and member of Palatin’s Audit and Compensation Committees. “Dr. Dunton brings Palatin both substantial drug development experience and clinical research experience,”